Bacterial redox systems and cellular macromolecules

Bacterial redox systems and cellular macromolecules represent a composite therapeutic target area exploited by redox-active antimicrobial agents (Source: NIH, 2022). This target involves the interaction between bacterial-specific enzymes, such as nitroreductases and ferredoxins, and the essential building blocks of the cell, including DNA, RNA, and proteins (Source: ASM, 2024). Drugs like nitrofurantoin and metronidazole act as prodrugs that are selectively reduced by these bacterial redox systems to generate highly reactive radical intermediates (Source: DrugBank). These intermediates then cause widespread oxidative damage or covalent modification of cellular macromolecules, leading to the inhibition of DNA synthesis, protein translation, and metabolic function (Source: ResearchGate, 2025). This multi-targeted mechanism is primarily used to treat infections caused by anaerobic bacteria and certain microaerophilic pathogens, where the specific redox environment facilitates drug activation (Source: StatPearls). While effective, the reliance on bacterial enzymes for activation means that resistance can emerge through mutations in the genes encoding these reductases, such as nfsA and nfsB (Source: PubMed). Additionally, the non-specific nature of the damage to macromolecules makes it difficult for bacteria to develop resistance through simple target site mutations, unlike many other antibiotic classes.

Other names

Bacterial nitroreductase-activated targetsBacterial oxidative stress targetsBacterial DNA and protein damageBacterial redox-active prodrug targets

Prodrug activation by bacterial reductases (redox systems) to form reactive intermediates that damage cellular macromolecules (DNA, RNA, proteins).